Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ERD03, with a dissociation constant (Kd) of 17±7 μM, effectively disrupts the EXOSC3-RNA interaction. It has been shown to induce a PCH1B-like phenotype in zebrafish embryos, making it a valuable tool for research into neurological disorders [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | ERD03, with a dissociation constant (Kd) of 17±7 μM, effectively disrupts the EXOSC3-RNA interaction. It has been shown to induce a PCH1B-like phenotype in zebrafish embryos, making it a valuable tool for research into neurological disorders [1]. |
In vitro | ERD03 at a concentration of 50 μM disrupts G-rich RNA and EXOSC3 interactions by approximately 18% and triggers notable spinal curvature, mirroring the PCH1B phenotype in zebrafish embryos. Additionally, this compound significantly increases ataxin1b mRNA levels (~6-fold) while moderately increasing ataxin1a mRNA levels in embryos. Furthermore, ERD03 leads to a reduction in zebrafish cerebellum size, resulting in cerebella that are half the size of those in control groups treated with DMSO. |
Molecular Weight | 339.43 |
Formula | C21H25NO3 |
CAS No. | 1377897-01-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ERD03 1377897-01-2 inhibitor inhibit